Protein and Drug Design

Publication signal: Artificial Intelligence in Drug Design: Emerging Trends and Applications

Actinium Therapy for Late-stage Aggressive Sarcomas (NCT07156565)

Novel 4-(pyrimidin-5-yl)benzaldehyde based α-acyloxy amides via optimized Passerini reaction: In vitro COX inhibition and computational validation

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (NCT04685616)

Largazole targets Musashi protein expression via miR-125b-5p and sensitizes triple-negative breast cancer cells to radiation

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma (NCT03937830)

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor (NCT05590689)

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (NCT05319730)

Engineering drug-responsive replication machinery for precise control of self-amplifying RNA

A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer (NCT07676162)